CEFTRIAXONE ALVOGEN POWDER FOR SOLUTION FOR INJECTION/ INFUSION 1G/VIAL

Product Information

Registration Status: Active

CEFTRIAXONE ALVOGEN POWDER FOR SOLUTION FOR INJECTION/ INFUSION 1G/VIAL is approved to be sold in Singapore with effective from 2014-11-20. It is marketed by ALVOGEN SINGAPORE PTE LTD, with the registration number of SIN14676P.

This product contains Ceftriaxone 1.0 g in the form of INJECTION, POWDER, FOR SOLUTION. It is approved for INTRAVENOUS, INTRAMUSCULAR use.

This product is manufactured by SHENZHEN ZHIJUN PHARMACEUTICAL CO. in CHINA.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Ceftriaxone

Description

A broad-spectrum cephalosporin antibiotic with a very long half-life and high penetrability to meninges, eyes and inner ears. [PubChem]

Indication

For the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staph

Mechanism of Action

Ceftriaxone works by inhibiting the mucopeptide synthesis in the bacterial cell wall. The beta-lactam moiety of Ceftriaxone binds to carboxypeptidases, endopeptidases, and transpeptidases in the bacterial cytoplasmic membrane. These enzymes are involved in cell-wall synthesis and cell division. By binding to these enzymes, Ceftriaxone results in the formation of of defective cell walls and cell death.

Clearance

* 0.58 - 1.45 L/h [healthy adults receiving 0.15-3 g of CEFTRIAXONE]

Active Ingredient/Synonyms

(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | Cefatriaxone | Ceftriaxona | Ceftriaxonum | Ceftriazone | Ceftriaxone |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank